Annovis Bio Stock Analysis

ANVS Stock  USD 12.64  0.48  3.95%   
Annovis Bio is undervalued with Real Value of 20.8 and Target Price of 46.0. The main objective of Annovis Bio stock analysis is to determine its intrinsic value, which is an estimate of what Annovis Bio is worth, separate from its market price. There are two main types of Annovis Bio's stock analysis: fundamental analysis and technical analysis.
The Annovis Bio stock is traded in the USA on New York Stock Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Annovis Bio is usually not traded on Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day. Annovis Stock trading window is adjusted to America/New York timezone.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Annovis Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
For more information on how to buy Annovis Stock please use our How to Invest in Annovis Bio guide.

Annovis Stock Analysis Notes

About 25.0% of the company shares are held by company insiders. The company recorded a loss per share of 5.14. Annovis Bio had not issued any dividends in recent years. Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania. Annovis Bio operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 3 people. For more info on Annovis Bio please contact Maria Maccecchini at 610 727 3913 or go to https://www.annovisbio.com.

Annovis Bio Investment Alerts

Annovis Bio is way too risky over 90 days horizon
Annovis Bio appears to be risky and price may revert if volatility continues
Annovis Bio has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (56.2 M) with profit before overhead, payroll, taxes, and interest of 0.
Annovis Bio currently holds about 35.97 M in cash with (39.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.41.
Annovis Bio has a poor financial position based on the latest SEC disclosures
Roughly 25.0% of the company shares are held by company insiders
Latest headline from benzinga.com: UniQure Soars on New Huntingtons Disease Study Data

Annovis Bio Upcoming and Recent Events

1st of April 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
1st of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Annovis Largest EPS Surprises

Earnings surprises can significantly impact Annovis Bio's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-05-10
2024-03-31-0.8-0.720.0810 
2021-11-03
2021-09-30-0.44-0.350.0920 
2021-03-03
2020-12-31-0.16-0.25-0.0956 
View All Earnings Estimates

Annovis Bio Environmental, Social, and Governance (ESG) Scores

Annovis Bio's ESG score is a quantitative measure that evaluates Annovis Bio's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Annovis Bio's operations that may have significant financial implications and affect Annovis Bio's stock price as well as guide investors towards more socially responsible investments.

Annovis Stock Institutional Investors

Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Northern Trust Corp2024-03-31
24.3 K
Merit Financial Group, Llc2024-03-31
22.2 K
Bank Of New York Mellon Corp2024-03-31
19.1 K
Spears Abacus Advisors Llc2024-03-31
15 K
Greenwich Wealth Management Llc2024-03-31
12.6 K
Lokken Investment Group Llc2024-03-31
12.2 K
Jane Street Group, Llc2023-12-31
12 K
Cetera Investment Advisers2024-03-31
11.2 K
Cetera Advisors Llc2024-03-31
10.2 K
Vanguard Group Inc2024-03-31
357.9 K
Adage Capital Partners Gp Llc2024-03-31
250 K
Note, although Annovis Bio's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Annovis Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 135.85 M.

Annovis Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(5.51)(5.23)
Return On Capital Employed(7.60)(7.22)
Return On Assets(5.51)(5.23)
Return On Equity 7.25  7.61 

Management Efficiency

Annovis Bio has return on total asset (ROA) of (1.6065) % which means that it has lost $1.6065 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.6649) %, meaning that it created substantial loss on money invested by shareholders. Annovis Bio's management efficiency ratios could be used to measure how well Annovis Bio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 7.61 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (5.23). At this time, Annovis Bio's Total Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 53.7 M in 2024, despite the fact that Return On Tangible Assets are likely to grow to (5.23).
Last ReportedProjected for Next Year
Book Value Per Share(0.86)(0.82)
Tangible Book Value Per Share(0.86)(0.82)
Enterprise Value Over EBITDA(3.62)(3.80)
Price Book Value Ratio(21.77)(20.68)
Enterprise Value Multiple(3.62)(3.80)
Price Fair Value(21.77)(20.68)
Enterprise Value163 M171.1 M
The analysis of Annovis Bio's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Annovis Bio's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Annovis Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta
1.741
Return On Assets
(1.61)
Return On Equity
(5.66)

Technical Drivers

As of the 16th of July 2024, Annovis Bio shows the Downside Deviation of 13.58, risk adjusted performance of 0.0627, and Mean Deviation of 10.26. Annovis Bio technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Annovis Bio downside deviation, treynor ratio, as well as the relationship between the Treynor Ratio and expected short fall to decide if Annovis Bio is priced correctly, providing market reflects its regular price of 12.64 per share. Given that Annovis Bio has jensen alpha of 1.27, we suggest you to validate Annovis Bio's prevailing market performance to make sure the company can sustain itself at a future point.

Annovis Bio Price Movement Analysis

Execute Study
The output start index for this execution was nine with a total number of output elements of fifty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Annovis Bio middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Annovis Bio. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Annovis Bio Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Annovis Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Annovis Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Annovis Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Annovis Bio Outstanding Bonds

Annovis Bio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Annovis Bio uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Annovis bonds can be classified according to their maturity, which is the date when Annovis Bio has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Annovis Bio Predictive Daily Indicators

Annovis Bio intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Annovis Bio stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Annovis Bio Corporate Filings

8K
10th of July 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
3rd of July 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
2nd of July 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
21st of June 2024
Other Reports
ViewVerify
8K
13th of June 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
11th of June 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
5th of June 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
21st of May 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify

Annovis Bio Forecast Models

Annovis Bio's time-series forecasting models are one of many Annovis Bio's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Annovis Bio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Annovis Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Annovis Bio prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Annovis shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Annovis Bio. By using and applying Annovis Stock analysis, traders can create a robust methodology for identifying Annovis entry and exit points for their positions.
Last ReportedProjected for Next Year

Current Annovis Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Annovis analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Annovis analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
46.0Buy5Odds
Annovis Bio current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Annovis analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Annovis stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Annovis Bio, talking to its executives and customers, or listening to Annovis conference calls.
Annovis Analyst Advice Details

Annovis Stock Analysis Indicators

Annovis Bio stock analysis indicators help investors evaluate how Annovis Bio stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Annovis Bio shares will generate the highest return on investment. By understating and applying Annovis Bio stock analysis, traders can identify Annovis Bio position entry and exit signals to maximize returns.
Begin Period Cash Flow28.4 M
Common Stock Shares OutstandingM
Total Stockholder Equity-7.8 M
Cash And Short Term Investments5.8 M
Cash5.8 M
Accounts Payable1.3 M
Net Debt-5.8 M
50 Day M A7.3194
Total Current Liabilities4.3 M
Other Operating Expenses45 M
Stock Based Compensation4.6 M

Additional Tools for Annovis Stock Analysis

When running Annovis Bio's price analysis, check to measure Annovis Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annovis Bio is operating at the current time. Most of Annovis Bio's value examination focuses on studying past and present price action to predict the probability of Annovis Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Annovis Bio's price. Additionally, you may evaluate how the addition of Annovis Bio to your portfolios can decrease your overall portfolio volatility.